Variable | OS before PSM | OS after PSM | ||||||
---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
P | P | HR | 95%CI | P | P | HR | 95%CI | |
Age (y), ≥/< 60 | 0.613 |  |  |  | 0.131 |  |  |  |
Gender (female/male) | 0.325 | Â | Â | Â | 0.776 | Â | Â | Â |
Etiology (others/HBV) | 0.161 | Â | Â | Â | 0.296 | Â | Â | Â |
PLT (109/L), ≥/<  100 | 0.994 |  |  |  | 0.356 |  |  |  |
PT (sec), ≥/<  13 | 0.069 | 0.047 | 1.167 | 1.002–1.359 | 0.087 | 0.003 | 1.425 | 1.128–1.800 |
AST (U/L), >/≤ 45 | 0.019 | 0.008 | 1.232 | 1.055–1.439 | 0.304 |  |  |  |
ALB (g/L), ≥/< 35 | 0.403 |  |  |  | 0.058 |  |  |  |
TBL (mmol/L), >/≤ 17 | 0.408 |  |  |  | 0.937 |  |  |  |
(C-P) grade A/B, C | 0.400 | Â | Â | Â | 0.338 | Â | Â | Â |
ALBI (grade2–3/ grade 1) | 0.027 | 0.002 | 1.246 | 1.084–1.431 | 0.810 |  |  |  |
AFP (ng/mL), ≥/<  400 | 0.119 |  |  |  | 0.291 |  |  |  |
Tumor size (cm) ≥/<  10 | 0.016 | 0.004 | 1.235 | 1.071–1.424 | 0.030 | 0.003 | 1.406 | 1.125–1.757 |
Tumor numbers (n), > 1/1 | 0.004 | 0.004 | 1.334 | 1.098–1.620 | 0.022 | 0.042 | 1.435 | 1.014–2.030 |
UICC stage IIIb /IIIa | 0.000 | 0.000 | 1.831 | 1.545–2.171 | 0.000 | 0.000 | 1.831 | 1.311–2.559 |
Year of treatment (10−/−09) | 0.056 | 0.039 | 0.860 | 0.746–0.993 | 0.163 |  |  |  |
Initial treatment (HR/TACE) | 0.000 | 0.000 | 0.677 | 0.569–0.806 | 0.000 | 0.000 | 0.646 | 0.522–0.798 |